All In Biotech

Drug Trial Radar · NCT05201066

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Actual

Start

Feb 28, 2023

Primary completion

Feb 14, 2028

Study completion Feb 14, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

Conditions

  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic

Interventions

  • decitabineDrug

    Solution for intravenous infusion

  • spartalizumabDrug

    Solution for intravenous infusion

  • sabatolimabDrug

    Solution for intravenous infusion

  • azacitidineDrug

    Solution for subcutaneous injection or intravenous infusion

  • venetoclaxDrug

    Tablet for oral administration

  • INQOVI (oral decitabine)Drug

    Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 5 years
  2. Severity of AEs and SAEsTime frame: 5 years

Locations

24 sites in 15 countries. Site status is shown where the registry gives one.

  • Oregon Health Sciences University

    Portland, Oregon

  • Huntsman Cancer Institute Univ of Utah

    Salt Lake City, Utah

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Florianópolis, Santa Catarina, Brazil

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Changchun, Jilin, China

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Alexandroupoli, Greece

  • Novartis Investigative Site

    Pátrai, Greece

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Fukushima, Japan

  • Novartis Investigative Site

    Kuala Lumpur, Malaysia

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Badalona, Barcelona, Spain

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.